{"transactions":[{"id":713368,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-07T23:00:06.000Z","date":"2026-07-06","kind":"exercise","planned":true,"acquired":false,"shares":12153,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":14140,"derivative":{"exercise_price":3.57,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":12153},"source":{"system":"sec-edgar","filing":"0001193125-26-297768","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526297768/ownership.xml","form_type":"4"}},{"id":713367,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-07T23:00:06.000Z","date":"2026-07-02","kind":"exercise","planned":true,"acquired":false,"shares":410,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":26293,"derivative":{"exercise_price":3.57,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":410},"source":{"system":"sec-edgar","filing":"0001193125-26-297768","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526297768/ownership.xml","form_type":"4"}},{"id":713366,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-07-07T23:00:06.000Z","date":"2026-07-06","kind":"exercise","planned":true,"acquired":true,"shares":12153,"price":3.57,"value":43386.21,"ownership":{"direct":true},"balance_after":98533,"source":{"system":"sec-edgar","filing":"0001193125-26-297768","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526297768/ownership.xml","form_type":"4"}},{"id":713365,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-07-07T23:00:06.000Z","date":"2026-07-02","kind":"sale","planned":true,"acquired":false,"shares":410,"price":7.01,"value":2874.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person. This transaction represents the final sale of shares needed to fully fund the exercise price and estimated tax withholding for the option exercises under this order of the plan and the remaining shares acquired upon exercise under this order will be held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.000 to $7.030, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":86380,"source":{"system":"sec-edgar","filing":"0001193125-26-297768","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526297768/ownership.xml","form_type":"4"}},{"id":713364,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-07-07T23:00:06.000Z","date":"2026-07-02","kind":"exercise","planned":true,"acquired":true,"shares":410,"price":3.57,"value":1463.7,"ownership":{"direct":true},"balance_after":86790,"source":{"system":"sec-edgar","filing":"0001193125-26-297768","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526297768/ownership.xml","form_type":"4"}},{"id":717123,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-03T00:17:03.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":26703,"derivative":{"exercise_price":3.57,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001193125-26-295150","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526295150/ownership.xml","form_type":"4"}},{"id":717122,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-03T00:17:03.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":23365,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":26803,"derivative":{"exercise_price":3.57,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":23365},"source":{"system":"sec-edgar","filing":"0001193125-26-295150","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526295150/ownership.xml","form_type":"4"}},{"id":717121,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T00:17:03.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":100,"price":7.07,"value":707.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person."}],"balance_after":86380,"source":{"system":"sec-edgar","filing":"0001193125-26-295150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526295150/ownership.xml","form_type":"4"}},{"id":717120,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T00:17:03.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":100,"price":3.57,"value":357.0,"ownership":{"direct":true},"balance_after":86480,"source":{"system":"sec-edgar","filing":"0001193125-26-295150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526295150/ownership.xml","form_type":"4"}},{"id":717119,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T00:17:03.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":23365,"price":7.08,"value":165424.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.00 to $7.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":86380,"source":{"system":"sec-edgar","filing":"0001193125-26-295150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526295150/ownership.xml","form_type":"4"}},{"id":717118,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T00:17:03.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":23365,"price":3.57,"value":83413.05,"ownership":{"direct":true},"balance_after":109745,"source":{"system":"sec-edgar","filing":"0001193125-26-295150","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526295150/ownership.xml","form_type":"4"}},{"id":718223,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":32930,"kind":"person","name":"Pandite Arundathy N.","position":1,"cik":"0001827232","reported_name":"Pandite Arundathy N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-03T00:15:04.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":7.01,"value":210300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.62 to $7.40, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":136219,"source":{"system":"sec-edgar","filing":"0001193125-26-295148","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827232/000119312526295148/ownership.xml","form_type":"4"}},{"id":737388,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-15T22:13:48.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":208333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock (\"Shares\") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5303908,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":208333},"source":{"system":"sec-edgar","filing":"0000947871-26-000626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000626/ownership.xml","form_type":"4"}},{"id":737387,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-15T22:13:48.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":1041667,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock (\"Shares\") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":26519541,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1041667},"source":{"system":"sec-edgar","filing":"0000947871-26-000626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000626/ownership.xml","form_type":"4"}},{"id":738328,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-15T22:12:04.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":208333,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock (\"Shares\") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5303908,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":208333},"source":{"system":"sec-edgar","filing":"0000947871-26-000625","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000625/ownership.xml","form_type":"4"}},{"id":738327,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-15T22:12:04.000Z","date":"2026-06-11","kind":"purchase","planned":false,"acquired":true,"shares":1041667,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 9, 2026, the Issuer announced a public offering of an aggregate of 10,879,376 shares of common stock (\"Shares\") at a price of $4.00 per Share and, in lieu of Shares to certain investors, pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 7,870,624 Shares at a price of $3.9999 per Pre-Funded Warrant. The Pre-Funded Warrant have an exercise price of $0.0001 per share and are exercisable at any time after the date of issuance. The public offering closed on June 11, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":26519541,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":1041667},"source":{"system":"sec-edgar","filing":"0000947871-26-000625","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000625/ownership.xml","form_type":"4"}},{"id":742044,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":28602,"kind":"person","name":"SIEGALL CLAY B","position":1,"cik":"0001167496","reported_name":"SIEGALL CLAY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-11T21:00:03.000Z","date":"2026-06-09","kind":"purchase","planned":false,"acquired":true,"shares":62500,"price":4,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of the Issuer's common stock purchased in connection with the Issuer's underwritten offering, which closed on June 11, 2026."}],"balance_after":318608,"source":{"system":"sec-edgar","filing":"0001193125-26-267836","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1167496/000119312526267836/ownership.xml","form_type":"4"}},{"id":745170,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2026-06-10T00:58:33.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":false,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if so elected by Reporting Persons, Pre-Funded Warrants. The price per Share and accompanying Common Warrant was $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant was $0.8676. On June 8, 2026, the Reporting Persons exercised their Common Warrants in exchange for an equal amount of Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-26-000615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000615/ownership.xml","form_type":"4"}},{"id":745169,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2026-06-10T00:58:33.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":false,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if so elected by Reporting Persons, Pre-Funded Warrants. The price per Share and accompanying Common Warrant was $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant was $0.8676. On June 8, 2026, the Reporting Persons exercised their Common Warrants in exchange for an equal amount of Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-26-000615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000615/ownership.xml","form_type":"4"}},{"id":745168,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-10T00:58:33.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":true,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if so elected by Reporting Persons, Pre-Funded Warrants. The price per Share and accompanying Common Warrant was $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant was $0.8676. On June 8, 2026, the Reporting Persons exercised their Common Warrants in exchange for an equal amount of Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5095575,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-26-000615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000615/ownership.xml","form_type":"4"}},{"id":745167,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-10T00:58:33.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":true,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if so elected by Reporting Persons, Pre-Funded Warrants. The price per Share and accompanying Common Warrant was $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant was $0.8676. On June 8, 2026, the Reporting Persons exercised their Common Warrants in exchange for an equal amount of Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":25477874,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-26-000615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787126000615/ownership.xml","form_type":"4"}},{"id":744207,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2026-06-10T00:56:11.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":false,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if elected, Pre-Funded Warrants. The price per Share and accompanying Common Warrant were $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant were $0.8676. On June 8, 2026, the Common Warrants were exercised in exchange for Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-26-000614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000614/ownership.xml","form_type":"4"}},{"id":744206,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2026-06-10T00:56:11.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":false,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if elected, Pre-Funded Warrants. The price per Share and accompanying Common Warrant were $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant were $0.8676. On June 8, 2026, the Common Warrants were exercised in exchange for Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-26-000614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000614/ownership.xml","form_type":"4"}},{"id":744205,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-10T00:56:11.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":true,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if elected, Pre-Funded Warrants. The price per Share and accompanying Common Warrant were $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant were $0.8676. On June 8, 2026, the Common Warrants were exercised in exchange for Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5095575,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-26-000614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000614/ownership.xml","form_type":"4"}},{"id":744204,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2026-06-10T00:56:11.000Z","date":"2026-06-08","kind":"exercise","planned":false,"acquired":true,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares or, if elected, Pre-Funded Warrants. The price per Share and accompanying Common Warrant were $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant were $0.8676. On June 8, 2026, the Common Warrants were exercised in exchange for Pre-Funded Warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":25477874,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-26-000614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787126000614/ownership.xml","form_type":"4"}},{"id":755334,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":42484,"kind":"person","name":"Baker Daniel G.","position":1,"cik":"0002046802","reported_name":"Baker Daniel G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T00:00:11.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":81000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-05-29","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001193125-26-254127","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046802/000119312526254127/ownership.xml","form_type":"4"}},{"id":754089,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":40806,"kind":"person","name":"Golumbeski George","position":1,"cik":"0001586660","reported_name":"Golumbeski George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T00:00:09.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":81000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-05-29","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001193125-26-254126","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586660/000119312526254126/ownership.xml","form_type":"4"}},{"id":754009,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T00:00:06.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP."}],"balance_after":81000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-05-29","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001193125-26-254124","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526254124/ownership.xml","form_type":"4"}},{"id":755407,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":28602,"kind":"person","name":"SIEGALL CLAY B","position":1,"cik":"0001167496","reported_name":"SIEGALL CLAY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T00:00:05.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":81000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-05-29","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001193125-26-254123","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1167496/000119312526254123/ownership.xml","form_type":"4"}},{"id":754747,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":30995,"kind":"person","name":"Boudreau Helen M","position":1,"cik":"0001661481","reported_name":"Boudreau Helen M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-03T00:00:03.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":81000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-05-29","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001193125-26-254122","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661481/000119312526254122/ownership.xml","form_type":"4"}},{"id":754161,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":38578,"kind":"person","name":"Gibson Neil W","position":1,"cik":"0001555918","reported_name":"Gibson Neil W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-02T20:00:08.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 81,000 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":81000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-05-29","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001193125-26-254125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555918/000119312526254125/ownership.xml","form_type":"4"}},{"id":762285,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":28602,"kind":"person","name":"SIEGALL CLAY B","position":1,"cik":"0001167496","reported_name":"SIEGALL CLAY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2026-05-27T10:05:29.000Z","date":"2026-05-22","kind":"exercise","planned":false,"acquired":false,"shares":128054,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":128054},"source":{"system":"sec-edgar","filing":"0001193125-26-240347","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1167496/000119312526240347/ownership.xml","form_type":"4"}},{"id":762284,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":28602,"kind":"person","name":"SIEGALL CLAY B","position":1,"cik":"0001167496","reported_name":"SIEGALL CLAY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-27T10:05:29.000Z","date":"2026-05-22","kind":"grant","planned":false,"acquired":true,"shares":128054,"price":1.0846,"value":138887.3684,"ownership":{"direct":true},"balance_after":256108,"source":{"system":"sec-edgar","filing":"0001193125-26-240347","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1167496/000119312526240347/ownership.xml","form_type":"4"}},{"id":767403,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2026-05-21T21:01:54.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":false,"shares":5122,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":5122},"source":{"system":"sec-edgar","filing":"0001193125-26-234774","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526234774/ownership.xml","form_type":"4"}},{"id":767402,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-21T21:01:54.000Z","date":"2026-05-21","kind":"grant","planned":false,"acquired":true,"shares":5122,"price":1.0846,"value":5555.3212,"ownership":{"direct":true},"balance_after":86380,"source":{"system":"sec-edgar","filing":"0001193125-26-234774","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526234774/ownership.xml","form_type":"4"}},{"id":775354,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":46510,"kind":"person","name":"Stout Stephen","position":1,"cik":"0001970664","reported_name":"Stout Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Warrants (Right to Buy)","published_at":"2026-05-18T07:46:20.000Z","date":"2026-05-15","kind":"exercise","planned":false,"acquired":false,"shares":12805,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":12805},"source":{"system":"sec-edgar","filing":"0001193125-26-227910","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970664/000119312526227910/ownership.xml","form_type":"4"}},{"id":775353,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":46510,"kind":"person","name":"Stout Stephen","position":1,"cik":"0001970664","reported_name":"Stout Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-18T07:46:20.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":12805,"price":1.0846,"value":13888.303,"ownership":{"direct":true},"balance_after":93366,"source":{"system":"sec-edgar","filing":"0001193125-26-227910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970664/000119312526227910/ownership.xml","form_type":"4"}},{"id":778635,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47238,"kind":"person","name":"Neill Andrew R","position":1,"cik":"0001827204","reported_name":"Neill Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2026-05-15T00:10:05.000Z","date":"2026-05-12","kind":"exercise","planned":false,"acquired":false,"shares":64027,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":64027},"source":{"system":"sec-edgar","filing":"0001193125-26-224692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526224692/ownership.xml","form_type":"4"}},{"id":778634,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47238,"kind":"person","name":"Neill Andrew R","position":1,"cik":"0001827204","reported_name":"Neill Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-15T00:10:05.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":64027,"price":1.0846,"value":69443.6842,"ownership":{"direct":true},"balance_after":292251,"source":{"system":"sec-edgar","filing":"0001193125-26-224692","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526224692/ownership.xml","form_type":"4"}},{"id":778633,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-15T00:05:03.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":false,"shares":2032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":50168,"derivative":{"exercise_price":3.57,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":2032},"source":{"system":"sec-edgar","filing":"0001193125-26-224686","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526224686/ownership.xml","form_type":"4"}},{"id":778632,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-15T00:05:03.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":2032,"price":7.01,"value":14244.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan.  Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.00 to $7.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":81258,"source":{"system":"sec-edgar","filing":"0001193125-26-224686","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526224686/ownership.xml","form_type":"4"}},{"id":778631,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-05-15T00:05:03.000Z","date":"2026-05-12","kind":"exercise","planned":true,"acquired":true,"shares":2032,"price":3.57,"value":7254.24,"ownership":{"direct":true},"balance_after":83290,"source":{"system":"sec-edgar","filing":"0001193125-26-224686","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526224686/ownership.xml","form_type":"4"}},{"id":779360,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":32930,"kind":"person","name":"Pandite Arundathy N.","position":1,"cik":"0001827232","reported_name":"Pandite Arundathy N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-05-15T00:00:03.000Z","date":"2026-05-12","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":6.61,"value":198300.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.41 to $7.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range"}],"balance_after":166219,"source":{"system":"sec-edgar","filing":"0001193125-26-224669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827232/000119312526224669/ownership.xml","form_type":"4"}},{"id":780418,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47597,"kind":"person","name":"Schreiber Taylor","position":1,"cik":"0001601942","reported_name":"Schreiber Taylor","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2026-05-13T10:05:13.000Z","date":"2026-05-12","kind":"exercise","planned":false,"acquired":false,"shares":25610,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."}],"balance_after":0,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":25610},"source":{"system":"sec-edgar","filing":"0001193125-26-220506","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1601942/000119312526220506/ownership.xml","form_type":"4"}},{"id":780417,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47597,"kind":"person","name":"Schreiber Taylor","position":1,"cik":"0001601942","reported_name":"Schreiber Taylor","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-13T10:05:13.000Z","date":"2026-05-12","kind":"grant","planned":false,"acquired":true,"shares":25610,"price":1.0846,"value":27776.606,"ownership":{"direct":true},"balance_after":122222,"source":{"system":"sec-edgar","filing":"0001193125-26-220506","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601942/000119312526220506/ownership.xml","form_type":"4"}},{"id":782840,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":46510,"kind":"person","name":"Stout Stephen","position":1,"cik":"0001970664","reported_name":"Stout Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-12T21:36:39.000Z","date":"2026-05-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":968,"price":6.85,"value":6630.8,"ownership":{"direct":true},"balance_after":80561,"source":{"system":"sec-edgar","filing":"0001193125-26-219935","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970664/000119312526219935/ownership.xml","form_type":"4"}},{"id":930111,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":32930,"kind":"person","name":"Pandite Arundathy N.","position":1,"cik":"0001827232","reported_name":"Pandite Arundathy N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-27T21:14:02.000Z","date":"2026-01-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":3195,"price":4.15,"value":13259.25,"ownership":{"direct":true},"balance_after":196219,"source":{"system":"sec-edgar","filing":"0001193125-26-024489","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827232/000119312526024489/ownership.xml","form_type":"4"}},{"id":930158,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":46510,"kind":"person","name":"Stout Stephen","position":1,"cik":"0001970664","reported_name":"Stout Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-01-27T21:11:08.000Z","date":"2026-01-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":593,"price":4.15,"value":2460.95,"ownership":{"direct":true},"balance_after":81529,"source":{"system":"sec-edgar","filing":"0001193125-26-024424","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970664/000119312526024424/ownership.xml","form_type":"4"}},{"id":929785,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47238,"kind":"person","name":"Neill Andrew R","position":1,"cik":"0001827204","reported_name":"Neill Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-27T21:05:02.000Z","date":"2026-01-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":2589,"price":4.15,"value":10744.35,"ownership":{"direct":true},"balance_after":228224,"source":{"system":"sec-edgar","filing":"0001193125-26-024393","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526024393/ownership.xml","form_type":"4"}},{"id":929788,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":68680,"kind":"person","name":"DeYoung Casi","position":1,"cik":"0001652066","reported_name":"DeYoung Casi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-27T16:08:02.000Z","date":"2026-01-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":2286,"price":4.15,"value":9486.9,"ownership":{"direct":true},"balance_after":73480,"source":{"system":"sec-edgar","filing":"0001193125-26-024409","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652066/000119312526024409/ownership.xml","form_type":"4"}},{"id":940156,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":46510,"kind":"person","name":"Stout Stephen","position":1,"cik":"0001970664","reported_name":"Stout Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T21:55:10.000Z","date":"2026-01-10","kind":"grant","planned":false,"acquired":true,"shares":351400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 351,400 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":351400,"derivative":{"exercise_price":4.75,"expiration_date":"2036-01-10","underlying":"Common Stock","underlying_shares":351400},"source":{"system":"sec-edgar","filing":"0001193125-26-011860","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970664/000119312526011860/ownership.xml","form_type":"4"}},{"id":940155,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":46510,"kind":"person","name":"Stout Stephen","position":1,"cik":"0001970664","reported_name":"Stout Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-01-13T21:55:10.000Z","date":"2026-01-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":4153,"price":4.75,"value":19726.75,"ownership":{"direct":true},"balance_after":82122,"source":{"system":"sec-edgar","filing":"0001193125-26-011860","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970664/000119312526011860/ownership.xml","form_type":"4"}},{"id":939887,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-01-13T21:48:00.000Z","date":"2026-01-10","kind":"grant","planned":false,"acquired":true,"shares":315500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 315,500 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":315500,"derivative":{"exercise_price":4.75,"expiration_date":"2036-01-10","underlying":"Common Stock","underlying_shares":315500},"source":{"system":"sec-edgar","filing":"0001193125-26-011847","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526011847/ownership.xml","form_type":"4"}},{"id":940124,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":32930,"kind":"person","name":"Pandite Arundathy N.","position":1,"cik":"0001827232","reported_name":"Pandite Arundathy N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-13T21:45:31.000Z","date":"2026-01-10","kind":"grant","planned":false,"acquired":true,"shares":487800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 487,800 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":487800,"derivative":{"exercise_price":4.75,"expiration_date":"2036-01-10","underlying":"Common Stock","underlying_shares":487800},"source":{"system":"sec-edgar","filing":"0001193125-26-011837","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1827232/000119312526011837/ownership.xml","form_type":"4"}},{"id":940123,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":32930,"kind":"person","name":"Pandite Arundathy N.","position":1,"cik":"0001827232","reported_name":"Pandite Arundathy N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-01-13T21:45:31.000Z","date":"2026-01-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":6851,"price":4.75,"value":32542.25,"ownership":{"direct":true},"balance_after":199414,"source":{"system":"sec-edgar","filing":"0001193125-26-011837","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827232/000119312526011837/ownership.xml","form_type":"4"}},{"id":939889,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47238,"kind":"person","name":"Neill Andrew R","position":1,"cik":"0001827204","reported_name":"Neill Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T21:42:08.000Z","date":"2026-01-10","kind":"grant","planned":false,"acquired":true,"shares":549800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 549,800 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":549800,"derivative":{"exercise_price":4.75,"expiration_date":"2036-01-10","underlying":"Common Stock","underlying_shares":549800},"source":{"system":"sec-edgar","filing":"0001193125-26-011828","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526011828/ownership.xml","form_type":"4"}},{"id":939888,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47238,"kind":"person","name":"Neill Andrew R","position":1,"cik":"0001827204","reported_name":"Neill Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-13T21:42:08.000Z","date":"2026-01-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":6660,"price":4.75,"value":31635.0,"ownership":{"direct":true},"balance_after":230813,"source":{"system":"sec-edgar","filing":"0001193125-26-011828","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312526011828/ownership.xml","form_type":"4"}},{"id":939906,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47597,"kind":"person","name":"Schreiber Taylor","position":1,"cik":"0001601942","reported_name":"Schreiber Taylor","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-13T21:40:01.000Z","date":"2026-01-10","kind":"grant","planned":false,"acquired":true,"shares":1548300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 1,548,300 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":1548300,"derivative":{"exercise_price":4.75,"expiration_date":"2036-01-10","underlying":"Common Stock","underlying_shares":1548300},"source":{"system":"sec-edgar","filing":"0001193125-26-011823","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601942/000119312526011823/ownership.xml","form_type":"4"}},{"id":939893,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":68680,"kind":"person","name":"DeYoung Casi","position":1,"cik":"0001652066","reported_name":"DeYoung Casi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-13T16:50:54.000Z","date":"2026-01-10","kind":"grant","planned":false,"acquired":true,"shares":381600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 381,600 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2027, with the remaining three quarters vesting in equal monthly installments through January 10, 2030, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":381600,"derivative":{"exercise_price":4.75,"expiration_date":"2036-01-10","underlying":"Common Stock","underlying_shares":381600},"source":{"system":"sec-edgar","filing":"0001193125-26-011853","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1652066/000119312526011853/ownership.xml","form_type":"4"}},{"id":939892,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":68680,"kind":"person","name":"DeYoung Casi","position":1,"cik":"0001652066","reported_name":"DeYoung Casi","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-01-13T16:50:54.000Z","date":"2026-01-10","kind":"tax_withholding","planned":false,"acquired":false,"shares":5699,"price":4.75,"value":27070.25,"ownership":{"direct":true},"balance_after":75766,"source":{"system":"sec-edgar","filing":"0001193125-26-011853","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1652066/000119312526011853/ownership.xml","form_type":"4"}},{"id":1051847,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3073298,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1051846,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":15366490,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1051845,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":2022277,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2022277,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":2022277},"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1051844,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":10111384,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":10111384,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":10111384},"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1051843,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":1051021,"price":0.8677,"value":911970.9217,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\"). OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1051021,"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1051842,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":24290,"kind":"person","name":"ORBIMED ADVISORS LLC","position":1,"cik":"0001055951","reported_name":"ORBIMED ADVISORS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24739,"kind":"person","name":"OrbiMed Capital GP IX LLC","position":2,"cik":"0001920574","reported_name":"OrbiMed Capital GP IX LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":24740,"kind":"person","name":"OrbiMed Genesis GP LLC","position":3,"cik":"0001808744","reported_name":"OrbiMed Genesis GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T01:52:10.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":5255106,"price":0.8677,"value":4559855.4762,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OrbiMed Private Investments IX, LP (\"OPI IX\"). OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya (\"Ashiya\"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5255106,"source":{"system":"sec-edgar","filing":"0000947871-25-000840","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055951/000094787125000840/ownership.xml","form_type":"4"}},{"id":1051151,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":3073298,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":3073298,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":3073298},"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051150,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Warrants (right to buy)","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":15366490,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":15366490,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":15366490},"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051149,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":2022277,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":2022277,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":2022277},"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051148,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Pre-Funded Warrants (right to buy)","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":10111384,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the OrbiMed Private Investments IX, LP (\"OPI IX\") and OrbiMed Genesis Master Fund, L.P. (\"Genesis Master Fund\") in a private placement which closed on August 25, 2025 (the \"Closing Date\") an aggregate of 6,306,127 shares of the Issuer's common stock (\"Shares\") and pre-funded warrants (\"Pre-Funded Warrants\") to purchase up to an aggregate of 12,133,661 Shares. OPI IX and Genesis Master Fund also received accompanying common warrants (\"Common Warrants\") to purchase up to an aggregate of 18,439,799 Shares. The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants are exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants will expire on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":10111384,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":10111384},"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051147,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":1051021,"price":0.8677,"value":911970.9217,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Genesis Master Fund. OrbiMed Genesis GP LLC (\"Genesis GP\") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":1051021,"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051146,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T01:50:52.000Z","date":"2025-08-25","kind":"purchase","planned":false,"acquired":true,"shares":5255106,"price":0.8677,"value":4559855.4762,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These securities are held of record by OPI IX. OrbiMed Capital GP IX LLC (\"GP IX\") is the general partner of OPI IX. OrbiMed Advisors LLC (\"OrbiMed Advisors\"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Reporting Person, OrbiMed Advisors, GP IX, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the \"Exchange Act\"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP IX, or Genesis GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":5255106,"source":{"system":"sec-edgar","filing":"0000947871-25-000839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000094787125000839/ownership.xml","form_type":"4"}},{"id":1051152,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":27989,"kind":"person","name":"Ashiya Mona","position":1,"cik":"0001794070","reported_name":"Ashiya Mona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-02T10:35:05.000Z","date":"2025-08-28","kind":"grant","planned":false,"acquired":true,"shares":66300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 66,300 shares of the Issuer's common stock, and vests in three equal annual installments on each of the first three anniversaries of August 28, 2025, subject to the Reporting Person's continued service to the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP."}],"balance_after":66300,"derivative":{"exercise_price":0.99,"expiration_date":"2035-08-28","underlying":"Common Stock","underlying_shares":66300},"source":{"system":"sec-edgar","filing":"0001193125-25-193328","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312525193328/ownership.xml","form_type":"4"}},{"id":1051725,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":42484,"kind":"person","name":"Baker Daniel G.","position":1,"cik":"0002046802","reported_name":"Baker Daniel G.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-02T10:35:03.000Z","date":"2025-08-28","kind":"grant","planned":false,"acquired":true,"shares":66300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 66,300 shares of the Issuer's common stock, and vests in three equal annual installments on each of the first three anniversaries of August 28, 2025, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":66300,"derivative":{"exercise_price":0.99,"expiration_date":"2035-08-28","underlying":"Common Stock","underlying_shares":66300},"source":{"system":"sec-edgar","filing":"0001193125-25-193327","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2046802/000119312525193327/ownership.xml","form_type":"4"}},{"id":1054688,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":46510,"kind":"person","name":"Stout Stephen","position":1,"cik":"0001970664","reported_name":"Stout Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Warrants (Right to Buy)","published_at":"2025-08-27T10:30:07.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":12805,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."}],"balance_after":12805,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":12805},"source":{"system":"sec-edgar","filing":"0001193125-25-189086","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1970664/000119312525189086/ownership.xml","form_type":"4"}},{"id":1054687,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":46510,"kind":"person","name":"Stout Stephen","position":1,"cik":"0001970664","reported_name":"Stout Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-08-27T10:30:07.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":12805,"price":0.8677,"value":11110.8985,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 12,805 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 12,805 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."}],"balance_after":86275,"source":{"system":"sec-edgar","filing":"0001193125-25-189086","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970664/000119312525189086/ownership.xml","form_type":"4"}},{"id":1054294,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47238,"kind":"person","name":"Neill Andrew R","position":1,"cik":"0001827204","reported_name":"Neill Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2025-08-27T10:30:06.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":64027,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."}],"balance_after":64027,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":64027},"source":{"system":"sec-edgar","filing":"0001193125-25-189088","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312525189088/ownership.xml","form_type":"4"}},{"id":1054293,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47238,"kind":"person","name":"Neill Andrew R","position":1,"cik":"0001827204","reported_name":"Neill Andrew R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-27T10:30:06.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":64027,"price":0.8677,"value":55556.2279,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 64,027 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 64,027 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."}],"balance_after":237473,"source":{"system":"sec-edgar","filing":"0001193125-25-189088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312525189088/ownership.xml","form_type":"4"}},{"id":1054758,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":28602,"kind":"person","name":"SIEGALL CLAY B","position":1,"cik":"0001167496","reported_name":"SIEGALL CLAY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2025-08-27T10:30:05.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":128054,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."}],"balance_after":128054,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":128054},"source":{"system":"sec-edgar","filing":"0001193125-25-189085","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1167496/000119312525189085/ownership.xml","form_type":"4"}},{"id":1054757,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":28602,"kind":"person","name":"SIEGALL CLAY B","position":1,"cik":"0001167496","reported_name":"SIEGALL CLAY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-27T10:30:05.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":128054,"price":0.8677,"value":111112.4558,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 128,054 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 128,054 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."}],"balance_after":128054,"source":{"system":"sec-edgar","filing":"0001193125-25-189085","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1167496/000119312525189085/ownership.xml","form_type":"4"}},{"id":1054302,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47597,"kind":"person","name":"Schreiber Taylor","position":1,"cik":"0001601942","reported_name":"Schreiber Taylor","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2025-08-27T10:30:04.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":25610,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."}],"balance_after":25610,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":25610},"source":{"system":"sec-edgar","filing":"0001193125-25-189087","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1601942/000119312525189087/ownership.xml","form_type":"4"}},{"id":1054301,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":47597,"kind":"person","name":"Schreiber Taylor","position":1,"cik":"0001601942","reported_name":"Schreiber Taylor","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-08-27T10:30:04.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":25610,"price":0.8677,"value":22221.797,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 25,610 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 25,610 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."}],"balance_after":96612,"source":{"system":"sec-edgar","filing":"0001193125-25-189087","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601942/000119312525189087/ownership.xml","form_type":"4"}},{"id":1054291,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Warrants (Right to Buy)","published_at":"2025-08-27T10:30:04.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":5122,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Warrants are exercisable at any time on or after the original issuance date until the 30th day following the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly."}],"balance_after":5122,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":5122},"source":{"system":"sec-edgar","filing":"0001193125-25-189084","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312525189084/ownership.xml","form_type":"4"}},{"id":1054290,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-08-27T10:30:04.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":5122,"price":0.8677,"value":4444.3594,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 4, 2025, the Issuer entered into a securities purchase agreement (the \"Purchase Agreement\") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer in a private placement, which closed on August 25, 2025, issued and sold to the Reporting Person 5,122 shares of the Issuer's common stock and accompanying warrants (the \"Warrants\") to purchase up to an aggregate of 5,122 shares of the Issuer's common stock at a combined price per share and accompanying Warrant of $0.8677."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 600 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the \"ESPP\") on February 15, 2025 and 2,000 shares acquired by the Reporting Person under the ESPP on August 15, 2025."}],"balance_after":81258,"source":{"system":"sec-edgar","filing":"0001193125-25-189084","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000119312525189084/ownership.xml","form_type":"4"}},{"id":1055599,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Warrants to Purchase Common Stock","published_at":"2025-08-26T21:00:29.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":4097730,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 25, 2025 (the \"Closing Date\"), pursuant to the terms of that certain securities purchase agreement, dated as of August 4, 2025 (the \"Purchase Agreement\") and following the satisfaction of certain material conditions set forth therein, the Issuer issued and sold to certain institutional investors in a private placement, including certain private investment vehicles managed by Redmile Group, LLC (the \"Redmile Clients\"), pre-funded warrants (the \"Pre-Funded Warrants\") to purchase shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"), accompanied by warrants (the \"Common Warrants\") to purchase an equal number of shares of Common Stock (or, in lieu thereof, Pre-Funded Warrants to purchase up to the same number of shares), at a combined purchase price for both securities of $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants and Common Warrants are exercisable by the holder at any time on or after the Closing Date, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants do not have an expiration date. The Common Warrants will expire 30 days after a public announcement of the data from the Issuer's Phase 1 clinical trial for SL-325 in healthy volunteers and the design of its Phase 2 clinical trial."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants and Common Warrants are exercisable by the holder at any time on or after the Closing Date, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants do not have an expiration date. The Common Warrants will expire 30 days after a public announcement of the data from the Issuer's Phase 1 clinical trial for SL-325 in healthy volunteers and the design of its Phase 2 clinical trial."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are directly owned by the Redmile Clients, and may be deemed beneficially owned by Redmile Group, LLC (\"Redmile\") as the investment manager of the Redmile Clients."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4097730,"derivative":{"exercise_price":1.0846,"underlying":"Common Stock","underlying_shares":4097730},"source":{"system":"sec-edgar","filing":"0001104659-25-083134","document":"tm2524352-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465925083134/tm2524352-2_4seq1.xml","form_type":"4"}},{"id":1055598,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrants to Purchase Common Stock","published_at":"2025-08-26T21:00:29.000Z","date":"2025-08-25","kind":"grant","planned":false,"acquired":true,"shares":4097730,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 25, 2025 (the \"Closing Date\"), pursuant to the terms of that certain securities purchase agreement, dated as of August 4, 2025 (the \"Purchase Agreement\") and following the satisfaction of certain material conditions set forth therein, the Issuer issued and sold to certain institutional investors in a private placement, including certain private investment vehicles managed by Redmile Group, LLC (the \"Redmile Clients\"), pre-funded warrants (the \"Pre-Funded Warrants\") to purchase shares of the Issuer's common stock, par value $0.0001 per share (the \"Common Stock\"), accompanied by warrants (the \"Common Warrants\") to purchase an equal number of shares of Common Stock (or, in lieu thereof, Pre-Funded Warrants to purchase up to the same number of shares), at a combined purchase price for both securities of $0.8676."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Pre-Funded Warrants and Common Warrants are exercisable by the holder at any time on or after the Closing Date, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants do not have an expiration date. The Common Warrants will expire 30 days after a public announcement of the data from the Issuer's Phase 1 clinical trial for SL-325 in healthy volunteers and the design of its Phase 2 clinical trial."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants and Common Warrants are exercisable by the holder at any time on or after the Closing Date, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants do not have an expiration date. The Common Warrants will expire 30 days after a public announcement of the data from the Issuer's Phase 1 clinical trial for SL-325 in healthy volunteers and the design of its Phase 2 clinical trial."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are directly owned by the Redmile Clients, and may be deemed beneficially owned by Redmile Group, LLC (\"Redmile\") as the investment manager of the Redmile Clients."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":7198553,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":4097730},"source":{"system":"sec-edgar","filing":"0001104659-25-083134","document":"tm2524352-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465925083134/tm2524352-2_4seq1.xml","form_type":"4"}},{"id":1086336,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":38144,"kind":"person","name":"Lee Michael Stewart","position":1,"cik":"0001748010","reported_name":"Lee Michael Stewart","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-17T01:01:32.000Z","date":"2025-07-14","kind":"grant","planned":false,"acquired":true,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) immediately prior to the next annual meeting of the Issuer's shareholders, subject to the Reporting Person's continued service to the Issuer through such date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The stock option was granted to Mr. Lee, a managing director of Redmile Group, LLC (\"Redmile\"), in connection with his service as a member of the Board of Directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":33150,"derivative":{"exercise_price":0.82,"expiration_date":"2035-07-14","underlying":"Common Stock","underlying_shares":33150},"source":{"system":"sec-edgar","filing":"0001104659-25-068454","document":"tm2521022-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000110465925068454/tm2521022-2_4seq1.xml","form_type":"4"}},{"id":1086459,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":25414,"kind":"organization","name":"Redmile Group, LLC","position":1,"cik":"0001425738","reported_name":"Redmile Group, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":25415,"kind":"person","name":"Green Jeremy","position":2,"cik":"0001650527","reported_name":"Green Jeremy","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-17T01:00:22.000Z","date":"2025-07-14","kind":"grant","planned":false,"acquired":true,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) immediately prior to the next annual meeting of the Issuer's shareholders, subject to Mr. Michael Lee's continued service to the Issuer through such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The stock option was granted to Mr. Lee, a managing director of Redmile Group, LLC (\"Redmile\"), in connection with his service as a member of the Board of Directors of the Issuer. Pursuant to the policies of Redmile, Mr. Lee holds this stock option as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option to Redmile. Mr. Lee disclaims beneficial ownership of the stock option, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The stock option may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option except to the extent of their pecuniary interest therein, if any, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":33150,"derivative":{"exercise_price":0.82,"expiration_date":"2035-07-14","underlying":"Common Stock","underlying_shares":33150},"source":{"system":"sec-edgar","filing":"0001104659-25-068453","document":"tm2521022-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1425738/000110465925068453/tm2521022-1_4seq1.xml","form_type":"4"}},{"id":1086776,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":28602,"kind":"person","name":"SIEGALL CLAY B","position":1,"cik":"0001167496","reported_name":"SIEGALL CLAY B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-16T20:28:22.000Z","date":"2025-07-14","kind":"grant","planned":false,"acquired":true,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":33150,"derivative":{"exercise_price":0.82,"expiration_date":"2035-07-14","underlying":"Common Stock","underlying_shares":33150},"source":{"system":"sec-edgar","filing":"0000950170-25-096284","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1167496/000095017025096284/ownership.xml","form_type":"4"}},{"id":1086355,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":40806,"kind":"person","name":"Golumbeski George","position":1,"cik":"0001586660","reported_name":"Golumbeski George","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-16T20:21:25.000Z","date":"2025-07-14","kind":"grant","planned":false,"acquired":true,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":33150,"derivative":{"exercise_price":0.82,"expiration_date":"2035-07-14","underlying":"Common Stock","underlying_shares":33150},"source":{"system":"sec-edgar","filing":"0000950170-25-096275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1586660/000095017025096275/ownership.xml","form_type":"4"}},{"id":1086335,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":51356,"kind":"person","name":"Brous Tyler","position":1,"cik":"0001827387","reported_name":"Brous Tyler","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-16T20:09:56.000Z","date":"2025-07-14","kind":"grant","planned":false,"acquired":true,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":33150,"derivative":{"exercise_price":0.82,"expiration_date":"2035-07-14","underlying":"Common Stock","underlying_shares":33150},"source":{"system":"sec-edgar","filing":"0000950170-25-096254","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000095017025096254/ownership.xml","form_type":"4"}},{"id":1086491,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":30995,"kind":"person","name":"Boudreau Helen M","position":1,"cik":"0001661481","reported_name":"Boudreau Helen M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-16T20:05:15.000Z","date":"2025-07-14","kind":"grant","planned":false,"acquired":true,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":33150,"derivative":{"exercise_price":0.82,"expiration_date":"2035-07-14","underlying":"Common Stock","underlying_shares":33150},"source":{"system":"sec-edgar","filing":"0000950170-25-096242","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1661481/000095017025096242/ownership.xml","form_type":"4"}},{"id":1086728,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":77484,"kind":"person","name":"Sasser Amy Kate","position":1,"cik":"0002013454","reported_name":"Sasser Amy Kate","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-16T16:25:25.000Z","date":"2025-07-14","kind":"grant","planned":false,"acquired":true,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":33150,"derivative":{"exercise_price":0.82,"expiration_date":"2035-07-14","underlying":"Common Stock","underlying_shares":33150},"source":{"system":"sec-edgar","filing":"0000950170-25-096280","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2013454/000095017025096280/ownership.xml","form_type":"4"}},{"id":1086378,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":38578,"kind":"person","name":"Gibson Neil W","position":1,"cik":"0001555918","reported_name":"Gibson Neil W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-16T16:17:54.000Z","date":"2025-07-14","kind":"grant","planned":false,"acquired":true,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":33150,"derivative":{"exercise_price":0.82,"expiration_date":"2035-07-14","underlying":"Common Stock","underlying_shares":33150},"source":{"system":"sec-edgar","filing":"0000950170-25-096273","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1555918/000095017025096273/ownership.xml","form_type":"4"}},{"id":1086685,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":77482,"kind":"person","name":"Brownstein Carrie","position":1,"cik":"0001894232","reported_name":"Brownstein Carrie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-16T16:13:31.000Z","date":"2025-07-14","kind":"grant","planned":false,"acquired":true,"shares":33150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents the right to purchase a total of 33,150 shares of the Issuer's common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":33150,"derivative":{"exercise_price":0.82,"expiration_date":"2035-07-14","underlying":"Common Stock","underlying_shares":33150},"source":{"system":"sec-edgar","filing":"0000950170-25-096266","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894232/000095017025096266/ownership.xml","form_type":"4"}},{"id":1292783,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-28T23:13:29.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":165200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase a total of 165,200 shares of the Issuer's common stock, one quarter of which will vest on January 28, 2026, with the remaining three quarters vesting in equal monthly installments through January 28, 2029, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":165200,"derivative":{"exercise_price":1.18,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":165200},"source":{"system":"sec-edgar","filing":"0000950170-25-010013","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000095017025010013/ownership.xml","form_type":"4"}},{"id":1292782,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":31624,"kind":"person","name":"Shukla Abhinav A.","position":1,"cik":"0001923377","reported_name":"Shukla Abhinav A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-01-28T23:13:29.000Z","date":"2025-01-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":2261,"price":1.16,"value":2622.76,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 600 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the \"ESPP\") on February 14, 2024 and 600 shares acquired by the Reporting Person under the ESPP on August 14, 2024."}],"balance_after":73536,"source":{"system":"sec-edgar","filing":"0000950170-25-010013","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1680367/000095017025010013/ownership.xml","form_type":"4"}},{"id":1293137,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":32930,"kind":"person","name":"Pandite Arundathy N.","position":1,"cik":"0001827232","reported_name":"Pandite Arundathy N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-28T23:04:53.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":206200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 206,200 shares of the Issuer's common stock, one quarter of which will vest on January 28, 2026, with the remaining three quarters vesting in equal monthly installments through January 28, 2029, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":206200,"derivative":{"exercise_price":1.18,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":206200},"source":{"system":"sec-edgar","filing":"0000950170-25-010004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1827232/000095017025010004/ownership.xml","form_type":"4"}},{"id":1293136,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":32930,"kind":"person","name":"Pandite Arundathy N.","position":1,"cik":"0001827232","reported_name":"Pandite Arundathy N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-01-28T23:04:53.000Z","date":"2025-01-25","kind":"tax_withholding","planned":false,"acquired":false,"shares":3211,"price":1.16,"value":3724.76,"ownership":{"direct":true},"balance_after":206265,"source":{"system":"sec-edgar","filing":"0000950170-25-010004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1827232/000095017025010004/ownership.xml","form_type":"4"}},{"id":1293240,"issuer":{"id":5224,"kind":"organization","name":"Shattuck Labs, Inc."},"owners":[{"id":46510,"kind":"person","name":"Stout Stephen","position":1,"cik":"0001970664","reported_name":"Stout Stephen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-28T23:02:04.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":177000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 177,000 shares of the Issuer's common stock, one quarter of which will vest on January 28, 2026, with the remaining three quarters vesting in equal monthly installments through January 28, 2029, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":177000,"derivative":{"exercise_price":1.18,"expiration_date":"2035-01-28","underlying":"Common Stock","underlying_shares":177000},"source":{"system":"sec-edgar","filing":"0000950170-25-010001","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1970664/000095017025010001/ownership.xml","form_type":"4"}}],"next_cursor":"2025-01-28T23:02:04.000000Z,1293240"}